Get started
CHINA MEDICAL SYSTEM HLDGS LTDCHINA MEDICAL SYSTEM HLDGS LTDCHINA MEDICAL SYSTEM HLDGS LTD

CHINA MEDICAL SYSTEM HLDGS LTD

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

867 chart


Full chart

867 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪18.35 B‬ HKD
Dividend yield (indicated)
3.32%
Price to earnings Ratio (TTM)
12.21
Basic EPS (TTM)
0.62 HKD
Net income (FY)
‪2.65 B‬ HKD
Revenue (FY)
‪8.85 B‬ HKD
Shares float
‪1.18 B‬
Beta (1Y)
0.94

Employees


Employees (FY)
‪5.7 K‬
Change (1Y)
+54 +0.96%
Revenue / Employee (1Y)
‪1.55 M‬ HKD
Net income / Employee (1Y)
‪465.36 K‬ HKD

About CHINA MEDICAL SYSTEM HLDGS LTD


Sector
Health Technology
CEO
Kong Lam
Headquarters
Shenzhen
Website
cms.net.cn
Founded
1995
FIGI
BBG0015X4QW2
China Medical System Holdings Ltd. engages in the production, marketing, promotion, and sale of drugs. Its products include Plendil, Ursofalk, Deanxit, Xinhuosu, Salofalk, BIOFLOR, Augentropfen Stulln Mono, Hirudoid, Combizym, Tanshinone Capsules, Yinuoshu, Nuodikang Capsules, Xidakang, Ganfule Capsules, Imdur, Parlodel, Elcitonin, Lamisil, Yinlian Qinggan Granules, MOVICOL. The company was founded by Kong Lam in January 1995 and is headquartered in Shenzhen, China.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

867 news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 867 is 7.48 HKD — it has decreased by −0.53% in the past 24 hours. Watch CHINA MEDICAL SYSTEM HLDGS LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange CHINA MEDICAL SYSTEM HLDGS LTD stocks are traded under the ticker 867.
867 stock has risen by 1.77% compared to the previous week, the month change is a −4.10% fall, over the last year CHINA MEDICAL SYSTEM HLDGS LTD has showed a −45.64% decrease.
We've gathered analysts' opinions on CHINA MEDICAL SYSTEM HLDGS LTD future price: according to them, 867 price has a max estimate of 13.56 HKD and a min estimate of 9.28 HKD. Watch 867 chart and read a more detailed CHINA MEDICAL SYSTEM HLDGS LTD stock forecast: see what analysts think of CHINA MEDICAL SYSTEM HLDGS LTD and suggest that you do with its stocks.
867 reached its all-time high on Jun 11, 2021 with the price of 22.80 HKD, and its all-time low was 2.51 HKD and was reached on Oct 11, 2010. View more price dynamics on 867 chart.
See other stocks reaching their highest and lowest prices.
867 stock is 2.95% volatile and has beta coefficient of 0.94. Track CHINA MEDICAL SYSTEM HLDGS LTD stock price on the chart and check out the list of the most volatile stocks — is CHINA MEDICAL SYSTEM HLDGS LTD there?
Today CHINA MEDICAL SYSTEM HLDGS LTD has the market capitalization of ‪18.17 B‬, it has increased by 1.62% over the last week.
Yes, you can track CHINA MEDICAL SYSTEM HLDGS LTD financials in yearly and quarterly reports right on TradingView.
CHINA MEDICAL SYSTEM HLDGS LTD is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
867 earnings for the last half-year are 0.40 HKD per share, whereas the estimation was 0.34 HKD, resulting in a 16.69% surprise. The estimated earnings for the next half-year are 0.37 HKD per share. See more details about CHINA MEDICAL SYSTEM HLDGS LTD earnings.
CHINA MEDICAL SYSTEM HLDGS LTD revenue for the last half-year amounts to ‪3.88 B‬ HKD, despite the estimated figure of ‪3.94 B‬ HKD. In the next half-year revenue is expected to reach ‪4.32 B‬ HKD.
867 net income for the last half-year is ‪986.56 M‬ HKD, while the previous report showed ‪518.44 M‬ HKD of net income which accounts for 90.30% change. Track more CHINA MEDICAL SYSTEM HLDGS LTD financial stats to get the full picture.
CHINA MEDICAL SYSTEM HLDGS LTD dividend yield was 3.09% in 2023, and payout ratio reached 39.56%. The year before the numbers were 4.98% and 39.56% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 30, 2024, the company has ‪5.70 K‬ employees. See our rating of the largest employees — is CHINA MEDICAL SYSTEM HLDGS LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CHINA MEDICAL SYSTEM HLDGS LTD EBITDA is ‪2.10 B‬ HKD, and current EBITDA margin is 36.18%. See more stats in CHINA MEDICAL SYSTEM HLDGS LTD financial statements.
Like other stocks, 867 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CHINA MEDICAL SYSTEM HLDGS LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CHINA MEDICAL SYSTEM HLDGS LTD technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CHINA MEDICAL SYSTEM HLDGS LTD stock shows the sell signal. See more of CHINA MEDICAL SYSTEM HLDGS LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.